Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bicara Therapeutics Inc. - Common Stock
(NQ:
BCAX
)
16.78
-0.84 (-4.77%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bicara Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 05, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
↗
August 18, 2026
Cash runway extends to 2029 as ficerafusp alfa advances toward interim analysis.
Via
The Motley Fool
Topics
Earnings
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 14, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates
↗
May 11, 2026
Via
Chartmill
Bicara Therapeutics Q2 Earnings Call Highlights
↗
August 11, 2026
Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of...
Via
MarketBeat
Topics
Earnings
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
August 11, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
August 04, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Top movers in Friday's after hours session
↗
July 31, 2026
Via
Chartmill
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
July 28, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
↗
June 13, 2026
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara (BCAX) Q4 2025 Earnings Transcript
↗
June 01, 2026
Bicara (BCAX) Q4 2025 Earnings Transcript
Via
The Motley Fool
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
↗
May 22, 2026
Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the...
Via
MarketBeat
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
May 21, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
↗
May 15, 2026
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
↗
May 15, 2026
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
↗
May 14, 2026
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development...
Via
MarketBeat
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara (BCAX) Q1 2026 Earnings Transcript
↗
May 11, 2026
Bicara (BCAX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Bicara Therapeutics Q1 Earnings Call Highlights
↗
May 11, 2026
Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while...
Via
MarketBeat
Topics
Earnings
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 11, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
↗
May 04, 2026
This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
May 04, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
↗
April 01, 2026
Via
Chartmill
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
↗
March 30, 2026
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.
↗
March 26, 2026
This Boston biotech innovator in bifunctional cancer therapies reported a notable insider sale, according to recent filings.
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 23, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
